BrightGene Bio-Medical's holding subsidiary, Atmen (Suzhou) Pharmaceutical, has received marketing authorization from the National Medical Products Administration for tiotropium bromide inhalation spray, becoming the first domestic company to win approval for this generic drug. The product is a Category 4 chemical drug, delivering 2.5 micrograms of tiotropium bromide per spray, with 60 sprays per bottle. The manufacturer is BrightGene Pharmaceutical (Suzhou), and the approval number is valid until July 27, 2031. The company stated that this approval further enriches its respiratory product pipeline and helps enhance market competitiveness. However, due to uncertainties such as industry policies and the market environment, the impact of this approval on the company's operating performance remains uncertain.
BrightGene Bio Medical Technology CFirst domestic generic approval for tiotropium bromide inhalation spray enriches respiratory pipeline and enhances competitiveness.
Subsidiary Atmen received marketing authorization for the generic drug, directly benefiting from the approval.